Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 10, 2016, Pages 1481-1489.e5

  Brouwer, Willem P ^a   Chan, Henry Lik Yuen ^b   Brunetto, Maurizia R ^c   Martinot Peignoux, Michelle ^d   Arends, Pauline ^a   Cornberg, Markus ^e   Cherubini, Beatrice ^c   Thompson, Alex J V ^f   Liaw, Yun Fan ^g   Marcellin, Patrick ^d   Janssen, Harry L A ^a,h   Hansen, Bettina E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF PISA   (Italy)

^d CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f ST VINCENT S HOSPITAL   (Australia)

^g CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^h TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Dynamic Prediction; HBe Antigen; HBs Antigen; Inactive Carrier

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; ALANINE AMINOTRANSFERASE; VIRUS DNA;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CHRONIC HEPATITIS B; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B VIRUS; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTIVE VALUE; PROBABILITY; RETROSPECTIVE STUDY; RISK FACTOR; TERTIARY CARE CENTER; VIRUS PATHOGENESIS; AGED; ASIA; AUSTRALIA; BLOOD; DIAGNOSTIC TEST; EUROPE; EVALUATION STUDY; HEPATITIS B, CHRONIC; HETEROZYGOTE; LONGITUDINAL STUDY; MIDDLE AGED; OUTPATIENT; PROCEDURES; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ALANINE TRANSAMINASE; ASIA; AUSTRALIA; CARRIER STATE; DIAGNOSTIC TESTS, ROUTINE; DNA, VIRAL; EUROPE; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTPATIENTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TERTIARY CARE CENTERS;

EID: 84991035790     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.01.019     Document Type: Article

References (26)

1. 1 European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
2. 2 Liaw, Y.F., Kao, J.H., Piratvisuth, T., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 6 (2012), 531–561.
3. 3 Lok, A.S., McMahon, B.J., Chronic hepatitis B: update 2009. Hepatology 50 (2009), 661–662.
4. 4 Chen, C.J., Yang, H.I., Su, J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006), 65–73.
5. 5 Fattovich, G., Olivari, N., Pasino, M., et al. Long-term outcome of chronic hepatitis B in caucasian patients: mortality after 25 years. Gut 57 (2008), 84–90.
6. 6 Iloeje, U.H., Yang, H.I., Su, J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006), 678–686.
7. 7 Tseng, T.C., Liu, C.J., Chen, C.L., et al. Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. J Infect Dis 208 (2013), 584–593.
8. 8 Tseng, T.C., Liu, C.J., Yang, H.C., et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 57 (2013), 441–450.
9. 9 Tseng, T.C., Liu, C.J., Yang, H.C., et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142 (2012), 1140–1149 e3 quiz e13–14.
10. 10 Brunetto, M.R., Oliveri, F., Colombatto, P., et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 139 (2010), 483–490.
11. 11 Martinot-Peignoux, M., Lapalus, M., Laouenan, C., et al. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. J Clin Virol 58 (2013), 401–407.
12. 12 Brunetto, M.R., Oliveri, F., Coco, B., et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 36 (2002), 263–270.
13. 13 Xiao, G., Yang, J., Yan, L., Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology 61 (2015), 292–302.
14. 14 Sonneveld, M.J., Rijckborst, V., Boucher, C.A., et al. A comparison of two assays for quantification of hepatitis B surface antigen in patients with chronic hepatitis B. J Clin Virol 51 (2011), 175–178.
15. 15 Chan, H.L., Wong, V.W., Wong, G.L., et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 52 (2010), 1232–1241.
16. 16 Jaroszewicz, J., Calle Serrano, B., Wursthorn, K., et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 52 (2010), 514–522.
17. 17 Nguyen, T., Thompson, A.J., Bowden, S., et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 52 (2010), 508–513.
18. 18 Brunetto, M.R., Marcellin, P., Cherubini, B., et al. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol 59 (2013), 1153–1159.
19. 19 Zoulim, F., Carosi, G., Greenbloom, S., et al. Quantification of HBsAg in nucleos(t)ide-naive patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. J Hepatol 62 (2015), 56–63.
20. 20 Su, T.H., Liu, C.J., Tseng, T.C., et al. Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection. PLoS One, 8, 2013, e55916.
21. 21 Zoutendijk, R., Hansen, B.E., van Vuuren, A.J., et al. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 204 (2011), 415–418.
22. 22 Chen, Y.C., Jeng, W.J., Chu, C.M., et al. Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin Gastroenterol Hepatol 10 (2012), 297–302.
23. 23 Seto, W.K., Wong, D.K., Fung, J., et al. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology 56 (2012), 812–819.
24. 1 Liaw, Y.F., Kao, J.H., Piratvisuth, T., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 6 (2012), 531–561.
25. 2 Udell, J.A., Wang, C.S., Tinmouth, J., et al. Does this patient with liver disease have cirrhosis?. JAMA 307 (2012), 832–842.
26. 3 Xiao, G., Yang, J., Yan, L., Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology 61 (2015), 292–302.